Relevant Publications

Planning for COVID-19 Vaccines Safety surveillance.  Kochhar S, Salmon D. Vaccine, 2020. https://doi.org/10.1016/j.vaccine.2020.07.013

Balancing Expediency and Scientific Rigor in SARS-CoV-2 Vaccine Development. Graepel KWKochhar SClayton EW et al.  J Infect Dis. 2020. pii: jiaa234. doi: 10.1093/infdis/jiaa234

Ethics of Conducting Clinical Research in an Outbreak Setting. Edwards KM, Kochhar S. Annu Rev Virol. 2020. doi: 10.1146/annurev-virology-013120-013123

Feasibility of Conducting Multi-Country Non-Interventional Vaccine Safety Studies in Asia-Pacific. Duszynski KM, Stark JH, Kochhar S et al. Accepted for publication in Pharmacoepidemiology and Drug Safety, 2020

The Brighton Collaboration Standardized Template for Collection of Key Information for Risk/Benefit Assessment of Nucleic Acid (RNA and DNA) Vaccines. Kim D, Robertson JS,…Kochhar S. Vaccine, 2020. https://doi.org/10.1016/j.vaccine.2020.06.017

The Brighton Collaboration Standardized Template for Collection of Key Information for Benefit-Risk Assessment of Protein Vaccines. Kochhar S, Kim D, Excler JL et al. Vaccine, 2020. https://doi.org/10.1016/j.vaccine.2020.06.044

The Brighton Collaboration Standardized Template for Collection of Key Information for Benefit-Risk Assessment of Inactivated viral vector vaccines. Kochhar S, Kim D, Excler JL et al. Vaccine, 2020. https://doi.org/10.1016/j.vaccine.2020.07.028

The Brighton Collaboration Standardized Template for Collection of Key Information for Benefit-Risk Assessment of Live-attenuated viral vaccines. Gurwith M, Condit R C, ..Kochhar S. Accepted for publication in Vaccine, 2020

Mapping age- and sex-specific HIV prevalence in sub-Saharan Africa over time. Accepted for publication in  Nature, 2020

The Brighton Collaboration standardized template for collection of key information for Benefit-Risk Assessment of Viral Vector Vaccines. Condit RC, Kim D, …Kochhar S. Accepted for publication in Vaccine, 2020

Standardized Templates for collection of key information for Benefit-Risk assessment of Vaccines. Chen R, Kochhar S, Condit RC. Submitted for publication to Vaccine, 2020

Group B streptococcal disease in the mother and newborn – a review. Steer PJ, Russell AB, Kochhar S, et a. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2020. https://doi.org/10.1016/j.ejogrb.2020.06.024

Global, regional, and national levels of neonatal, infant, and under-5 all-cause and cause-specific mortality, 1990–2019: findings from the Global Burden of Disease Study 2019. Kassebaum N, Kochhar S et al. Accepted for publication in Lancet, 2020

Global, regional, and national sex‐specific mortality, life expectancy, and non‐fatal burden of diseases and injuries for adults 70 years and older: a systematic analysis for the Global Burden of Disease 2017 Study. Tyrovolas S, Kotsakis G, ..Kochhar S et al. Accepted for publication in The Lancet, 2020

Mapping HIV incidence and mortality in 1sub-Saharan Africa between 2000 and 2018. Dwyer-Lindgren L, ..Kochhar S et al. Accepted for publication in AIDS, 2020

The use of a Speaking Book to enhance vaccine knowledge among caregivers in The Gambia. Nkereuwem O, Kochhar S, Wariri O et al. Accepted for publication by BMJ Global Health, 2020

Obstetrics Risk Assessment: Evaluation of Selection Criteria for Vaccine Research Studies in Pregnant Women. Eckert LO, Jones CE, Kochhar S et al. Vaccine. 2020, 38 (29): 4542-4547. https://doi.org/10.1016/j.vaccine.2020.05.022

Mapping geographic inequalities in access to drinking water and1 sanitation facilities in low‐ and middle‐income countries, 2000–20172. Deshpande A, Hay S, Kochhar S et al. Accepted for publication by The Lancet Global Health

Mapping geographic inequalities in oral rehydration therapy coverage in low- and middle-income countries, 2000–2017. Hay SI, Reiner RC, Kochhar S et al. Accepted for publication by The Lancet Global Health, 2020

Mapping child growth failure across low- and middle-income countries. Kinyoki DKOsgood-Zimmerman AE, ..Kochhar S et al. Nature. 2020; 577(7789):231-234. doi: 10.1038/s41586-019-1878-8

The unfulfilled promise of prevention: the global burden of 87 risk factors, 1990–2019; a systematic analysis for the Global Burden of Disease Study 2019. Murray C, ..Kochhar S et al. Accepted for publication in The Lancet, 2020

Mapping infectious disease burden among African children from 2000 to 2017. Accepted for publication by Nature, 2020

Global, regional and national mortality among adolescents and young people aged 10 to 24 years, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Accepted for publication by Nature, 2020

Five Insights from the Global Burden of Disease Study 2019. Accepted for publication by The Lancet, 2020

Measuring universal health coverage using the UHC effective coverage index in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Kochhar S et al. Accepted for publication by The Lancet, 2020

Global, regional, and national sex-specific mortality, life expectancy, and non-fatal burden of diseases and injuries for adults 70 years and older: a systematic analysis for the Global Burden of Disease 2017 Study. Tyrovolas S, Kotsakis GA, Kochhar S et al. Accepted for publication in The Lancet, 2020

Introduction of New Vaccines for Immunization in Pregnancy- Programmatic, Regulatory and Safety Considerations. Kochhar S, Edwards K, Ortiz J et al. Vaccine 2019, 37:25, 3267-3277. https://doi.org/10.1016/j.vaccine.2019.04.075

Immunization in Pregnancy Safety Surveillance in Low and Middle Income Countries- Field Performance and Validation of Novel Case Definitions. Kochhar S, Clarke E, Izu A et al. Vaccine 2019. 37:22, 2967-2974. https://doi.org/10.1016/j.vaccine.2019.03.074

Pregnant Women and Vaccines against Emerging Epidemic Threats: Ethics Guidance for Preparedness, Research, and Response. Krubiner C, Faden R, Kochhar S et al. Vaccine 2019. pii: S0264-410X(19)30045-3. doi: 10.1016/j.vaccine.2019.01.011.

Global, regional, and national incidence, prevalence, and mortality of HIV from 1980 to 2017 with forecasts to 2030, for 195 countries and 2 territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2017 Study. Murray C, Kochhar S et al. Accepted for publication in The Lancet HIV, 2019

Quantifying risks and interventions that have reduced mortality due to diarrhea among children younger than 5 years old: An analysis of the Global Burden of Disease study 2017. Reiner R, Kochhar S et al.  Accepted for publication in The Lancet Infectious Diseases, 2019

Quantifying risks and interventions to prevent and protect against lower respiratory infection health-loss among children younger than 5 years old: An analysis of the Global Burden of Disease study 2017. Reiner R, Kochhar S et al. Accepted for publication in The Lancet Infectious Diseases, 2019

Mapping child growth failure across low-and middle-income countries-2000- 2017. Local Burden of Disease Child Growth Failure Collaborators. Accepted for publication in Nature, 2019

Chorioamnionitis: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data. Bonhoeffer J, Kachikis A, Kochhar S et al. Accepted for publication in Vaccine, 2019

Neurodevelopmental Delay: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data. Bonhoeffer J, Villagomez AN, Kochhar S et al. Accepted for publication in Vaccine, 2019

Postpartum Endometritis and Infection following Incomplete or Complete Abortion. Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Maternal Immunization Safety Data. Bonhoeffer J, Rouse C, Kochhar S et al. Accepted for publication in Vaccine, 2019

Neonatal seizures: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety. Bonhoeffer J, Pellegrin S, Kochhar S et al. Accepted for publication in Vaccine, 2019

Diseases, Injuries, and Risk Factors in Child and Adolescent Health, 1990 to 2017 Findings from the Global Burden of Diseases, Injuries, and Risk Factors 2017 Study. Reiner RC JrOlsen HE, Kochhar S et al. JAMA Pediatr. 2019:e190337. doi: 10.1001/jamapediatrics.2019.0337

Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 Population and Fertility CollaboratorsMurray CJLCallender CSKH, Kochhar S et al. Lancet. 2018; 392(10159):1995-2051. doi: 10.1016/S0140-6736(18)32278-5.

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 DALYs and HALE CollaboratorsKyu HHAbate D, Kochhar S et al. Lancet. 2018; 392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3.

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 Risk Factor Collaborators- Stanaway JDAfshin A, Kochhar S et al. Lancet. 2018, 392(10159):1923-1994. doi: 10.1016/S0140-6736(18)32225-6.

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Lower Respiratory Infections CollaboratorsTroeger CBlacker B, Kochhar S et al. Lancet Infectious Diseases, , 18(11): 1191-1210, 2018. doi: 10.1016/S1473-3099(18)30310-4

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 DALYs and HALE Collaborators- Kyu HH, Abate D, Kochhar S et al. Lancet. 2018;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3

Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017.GBD 2017 Population and Fertility Collaborators- Murray CJL, Callender CSKH, Kochhar S et al. Lancet. 2018;392(10159):1995-2051. doi: 10.1016/S0140-6736(18)32278-5

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 Mortality Collaborators- Dicker D, Nguyen G, Kochhar S et al. Lancet. 2018;392(10159):1684-1735. doi: 10.1016/S0140-6736(18)31891-9

Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 SDG Collaborators-Lozano R, Fullman N,  Kochhar S et al. Lancet. 2018;392(10159):2091-2138. doi: 10.1016/S0140-6736(18)32281-5.

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017.GBD 2017 Causes of Death Collaborators- Roth GA, Abate D, Kochhar S et al. Lancet. 2018, 392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7.

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators-  James SL, Abate D, Kochhar S et al. Lancet. 2018;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7

Assessing the mortality, morbidity, and hospitalisations due to influenza lower respiratory infections from 1990 to 2017: an analysis from the Global Burden of Disease Study 2017. GBD 2017 Influenza Collaborators. Accepted for publication in Lancet 2018

Postpartum endometritis: development of a maternal outcome definition for international immunization research through the GAIA project. RouseE., Kachikis A, Kochhar S et al. American Journal of Obstetrics and Gynecology. 2018, 219: 6, 654- 655. DOI: https://doi.org/10.1016/j.ajog.2018.10.065

Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. GBD Tuberculosis Collaborators -Kyu HH, Maddison ER,  Kochhar S et al. The Lancet Infectious Diseases.  2018, 18:12, 1329-1349. DOI: doi: 1016/S1473-3099(18)30625-X

Chorioamnionitis: development of a maternal outcome definition for international immunization research through the GAIA project. Kachikis A, Eckert LO,  Kochhar S et al. American Journal of Obstetrics and Gynecology. 2018, 219: 6, 654. DOI: https://doi.org/10.1016/j.ajog.2018.10.064

Defining the interval for monitoring potential adverse events following immunisation (AEFIs) after receipt of live viral vectored vaccines. Kochhar S, Excler JL, Bok K et al. Vaccine. 2018. pii: S0264-410X(18)31235-0. doi: 10.1016/j.vaccine.2018.08.085.

Assessing feasibility of resources at health facilities in Uganda to diagnose pregnancy and neonatal outcomes. Stark JH, Wool E, Kochhar S et al. Int Health. 2018. doi: 10.1093/inthealth/ihy066.

Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. Ndaya-Oloo P, Pitisuttithum P, Kochhar S et al. J Clin Pharmacol. 2018 Oct;58 Suppl 10:S123-S139. doi: 10.1002/jcph.1140.

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Lower Respiratory Infections Collaborators- Troeger C, Blacker BF, Kochhar S et al. Lancet Infect Dis. 2018. pii: S1473-3099(18)30310-4. doi: 10.1016/S1473-3099(18)30310-4

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Diarrhoeal Disease Collaborators- Troeger C, Blacker BF, Kochhar S et al. Lancet Infect Dis. 2018. pii: S1473-3099(18)30362-1. doi: 10.1016/S1473-3099(18)30362-1

Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Alcohol Collaborators- Griswold MG, Fullman N, Kochhar S et al. Lancet. 2018;392(10152):1015-1035. doi: 10.1016/S0140-6736(18)31310-2

Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. GBD 2016 Healthcare Access and Quality Collaborators. Lancet. 2018;391(10136):2236-2271. doi: 10.1016/S0140-6736(18)30994-2.

Immunization in Pregnancy Clinical Research in Low- and Middle-Income Countries – Study Design, Regulatory and Safety Considerations. Kochhar S, Bonhoeffer J, Jones C et al. Vaccine pii: S0264-410X(17)30504-2, 2017

Editorial – Safety assessment of immunization in pregnancy. Kochhar S, Bauwens J, Bonhoeffer J. Vaccine. 2017;35(48 Pt A):6469-6471. doi: 10.1016/j.vaccine.2017.09.033.

Spontaneous abortion and ectopic pregnancy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Rouse CE, Eckert LO, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6563-6574. doi: 10.1016/j.vaccine.2017.01.047.

Gestational diabetes mellitus: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Kachikis A, Eckert LO, Kochhar S et al. Vaccine. 2017 ;35(48 Pt A):6555-6562. doi: 10.1016/j.vaccine.2017.01.043.

Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Easter SR, Eckert LO, Kochhar S et al.  Vaccine. 2017;35(48 Pt A):6546-6554. doi: 10.1016/j.vaccine.2017.01.042.

Dysfunctional labor: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Boatin AA, Eckert LO, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6538-6545. doi: 10.1016/j.vaccine.2017.01.050.

Antenatal bleeding: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Prabhu M, Eckert LO, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6529-6537. doi: 10.1016/j.vaccine.2017.01.081.

 Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Schlaudecker EP, Munoz FM, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6518-6528. doi: 10.1016/j.vaccine.2017.01.040.

Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Sweet LR, Keech C, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6506-6517. doi: 10.1016/j.vaccine.2017.01.046.

Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Sell E, Munoz FM, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6501-6505. doi: 10.1016/j.vaccine.2017.01.045.

Low birth weight: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Cutland CL, Lackritz EM, Kochhar S et al. Vaccine. 2017 ;35(48 Pt A):6492-6500. doi: 10.1016/j.vaccine.2017.01.049.

Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Ross E, Munoz FM, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6483-6491. doi: 10.1016/j.vaccine.2017.01.051.

Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation. DeSilva M, Munoz FM, Kochhar S et al. Vaccine. 2017;35(48 Pt A):6472-6482. doi: 10.1016/j.vaccine.2017.01.044.

Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Jones CE, Munoz FM, Kochhar S et al. Vaccine, 34(49):5998-6006, 2016

Guidance for collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy. Jones CE, Munoz FM, Kochhar S et al. Vaccine, 34(49):6007-6014, 2016

Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Clarke DK, Hendry RM, Kochhar S et al. Vaccine, 34(51):6597-6609, 2016

Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. Klug B, Robertson JS, Kochhar S et al. Vaccine, 34(51):6617-6625, 2016

The importance of the patient voice in vaccination and vaccine safety-are we listening? Holt DBouder FKochhar S et al. Clin Microbiol Infect. 22 Suppl 5:S146-S153, 2016

Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Felicetti PTrotta FKochar S et al. Vaccine, 34(51):6634-6640, 2016

Neonatal Infections: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data. Vergnano S, Buttery J, Kochhar S et al. Vaccine, 34(49):6038-6046, 2016

Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. DeSilva M, Munoz FM, Kochhar S et al. Vaccine, 34(49):6015-6026, 2016

Global Alignment of Immunization Safety Assessment in Pregnancy – The GAIA project. Bonhoeffer J, Kochhar S, Hirschfeld S et al. Vaccine, 34(49):5993-5997, 2016

Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Gravett C, Eckert LO, Kochhar S et al. Vaccine, 34(49):6084-6092, 2016

Neonatal death: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Pathirana J, Muñoz FM, Kochhar S et al. Vaccine, 34(49):6027-603, 2016

Preterm Birth: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunisation Safety Data. Quinn JA, Munoz FM, Kochhar S et al. Vaccine, 34(49):6047-6056, 2016

Postpartum haemorrhage: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Kerr R, Eckert LO, Kochhar S et al. Vaccine, 34(49):6102-6109, 2016.

Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data. Da Silva FT, Gonik B, Kochhar S et al. Vaccine, 34(49):6057-6068, 2016

Hypertensive disorders of pregnancy: Case definitions & guidelines for data collection, analysis, and presentation of immunization safety data. Rouse CE, Eckert LO, Kochhar S et al. Vaccine, 34(49):6069-6076, 2016

Pathways to Preterm Birth: Case Definition & Guidelines for Data Collection, Analysis, and Presentation of Immunisation Safety Data. Harrison MS, Eckert LO, Kochhar S et al. Vaccine, 34(49):6093-6101, 2016

Maternal death: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Patwardhan M, Eckert LO, Spiegel H, Pourmalek F, Cutland C, Kochhar S et al. Vaccine. 2016;34(49):6077-6083. doi: 10.1016/j.vaccine.2016.03.042.

Global lessons from Nigeria’s ebolavirus control strategy. Elemuwa C, Kutalek R, Ali M, Mworozi E, Kochhar S, et al. Expert Rev Vaccines. 2015, 24:1-4.

Communicating vaccine safety during the development and introduction of vaccines. Kochhar S. Curr Drug Saf. 2015, 10(1):55-9.

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh. Jamil KM, Haque R, Kochhar S et al. PLoS Negl Trop Dis.9(10):e0004118, 2015.

Pharmacokinetics and Tolerability of iOWH032, an Inhibitor of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel, in Normal Volunteers and Cholera Patients. Ullrich Schwertschlag, Amresh Kumar, Sonali Kochhar et al. Gastroentrology.  146, 5, Suppl 1, S-663, 2014

Standardization and simplification of vaccination records. Maurer W, Seeber L, Rundblad G, Kochhar S et al. Expert Rev Vaccines. 2014, 13(4):545-59.

Introducing new vaccines in developing countries. Kochhar S, Rath B, Seeber LD, Rundblad G, et al. Expert Rev Vaccines. 2013, 12(12):1465-78.

Template protocol for clinical trials investigating vaccines–focus on safety elements.
Bonhoeffer J, Imoukhuede EB, Aldrovandi G, Kochhar S, et al. Vaccine. 2013, 31(47):5602-20.

Impact, challenges, and future projections of vaccine trials in Africa. Idoko OT, Kochhar S, Agbenyega TE, Ogutu B, Ota MO. Am J Trop Med Hyg. 2013, 88(3):414-9.

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. Mehendale S, Thakar M, Sahay S, Kochhar S, et al. PLoS One. 2013, 8(2):e55831.

Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon. Kochhar S. Hum Vaccin Immunother. 2013, 9(4):928-31.

Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon. Kochhar S. Hum Vaccin Immunother. 2013, 9(4):924-7.

Prioritizing polio. Rath B, Ali M, Elemuwa C, Kochhar S, et al. Expert Rev Vaccines. 2012, 11(12):1389-92.

Promoting evidence-based vaccine safety research and communication. Rath B, Ali M, Codarini G, Elemuwa C, Kochhar S, et al. J Trop Pediatr. 2012, 58(3):167-9.

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Schmidt C, Smith C, Barin B, Kochhar S, et al. Hum Vaccin Immunother. 2012, 8(5):630-8.

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Gershman MD, Staples JE, Bentsi-Enchill AD, Brighton Collaboration Viscerotropic Disease Working Group. Vaccine. 2012, 30(33):5038-58. s

Safety reporting in developing country vaccine clinical trials-a systematic review. Muehlhans S, Richard G, Ali M, Kochhar S, et al. Vaccine. 2012, 30(22):3255-65.

AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. Kent SJ, Cooper DA, Chhi Vun M, AIDS Vaccine for Asia Network investigators, et al. PLoS Med. 2010, 7(9):e1000331.

Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Mehendale S, Sahay S, Thakar M, Kochhar S, et al. Indian J Med Res. 2010, 132:168-75.

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. Ramanathan VD, Kumar M, Mahalingam J, Kochhar S, et al. AIDS Res Hum Retroviruses. 2009, 25(11):1107-16.

Preparedness for AIDS vaccine trials in India. Excler JL, Kochhar S, Kapoor S, Das S, et al.
Indian J Med Res. 2008, 127(6):531-8.

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. Mehendale S, van Lunzen J, Clumeck N, Kochhar S, et al. AIDS Res Hum Retroviruses. 2008, 24(6):873-80.

Global lessons from Nigeria’s ebolavirus control strategy. Elemuwa C, Kutalek R, Ali M, Mworozi E, Kochhar S, et al. Expert Rev Vaccines. 2015, 24:1-4.

Communicating vaccine safety during the development and introduction of vaccines. Kochhar S. Curr Drug Saf. 2015, 10(1):55-9.

Standardization and simplification of vaccination records. Maurer W, Seeber L, Rundblad G, Kochhar S et al. Expert Rev Vaccines. 2014, 13(4):545-59.

Introducing new vaccines in developing countries. Kochhar S, Rath B, Seeber LD, Rundblad G, et al. Expert Rev Vaccines. 2013, 12(12):1465-78.

Template protocol for clinical trials investigating vaccines–focus on safety elements.
Bonhoeffer J, Imoukhuede EB, Aldrovandi G, Kochhar S, et al. Vaccine. 2013, 31(47):5602-20.

Impact, challenges, and future projections of vaccine trials in Africa. Idoko OT, Kochhar S, Agbenyega TE, Ogutu B, Ota MO. Am J Trop Med Hyg. 2013, 88(3):414-9.

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. Mehendale S, Thakar M, Sahay S, Kochhar S, et al. PLoS One. 2013, 8(2):e55831.

Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon. Kochhar S. Hum Vaccin Immunother. 2013, 9(4):928-31.

Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon. Kochhar S. Hum Vaccin Immunother. 2013, 9(4):924-7.

Prioritizing polio. Rath B, Ali M, Elemuwa C, Kochhar S, et al. Expert Rev Vaccines. 2012, 11(12):1389-92.

Promoting evidence-based vaccine safety research and communication. Rath B, Ali M, Codarini G, Elemuwa C, Kochhar S, et al. J Trop Pediatr. 2012, 58(3):167-9.

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Schmidt C, Smith C, Barin B, Kochhar S, et al. Hum Vaccin Immunother. 2012, 8(5):630-8.

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Gershman MD, Staples JE, Bentsi-Enchill AD, Brighton Collaboration Viscerotropic Disease Working Group. Vaccine. 2012, 30(33):5038-58. s

Safety reporting in developing country vaccine clinical trials-a systematic review. Muehlhans S, Richard G, Ali M, Kochhar S, et al. Vaccine. 2012, 30(22):3255-65.

AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. Kent SJ, Cooper DA, Chhi Vun M, AIDS Vaccine for Asia Network investigators, et al. PLoS Med. 2010, 7(9):e1000331.

Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Mehendale S, Sahay S, Thakar M, Kochhar S, et al. Indian J Med Res. 2010, 132:168-75.

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. Ramanathan VD, Kumar M, Mahalingam J, Kochhar S, et al. AIDS Res Hum Retroviruses. 2009, 25(11):1107-16.

Preparedness for AIDS vaccine trials in India. Excler JL, Kochhar S, Kapoor S, Das S, et al.
Indian J Med Res. 2008, 127(6):531-8.

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. Mehendale S, van Lunzen J, Clumeck N, Kochhar S, et al. AIDS Res Hum Retroviruses. 2008, 24(6):873-80.